Ambica Parmar1, Abdul Aziz Qazi2, Audrius Stundzia3, Hao-Wen Sim4,5,6,7, Jeremy Lewin8, Ur Metser2, Martin O'Malley2, Aaron R Hansen8. 1. Division of Medical Oncology & Hematology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada. 2. Department of Medical Imaging, University of Toronto, Toronto, ON, Canada. 3. Tomographix IP Ltd, Toronto, ON, Canada. 4. NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia. 5. St Vincent's Clinical School, University of New South Wales, Sydney, Australia. 6. Department of Medical Oncology, The Kinghorn Cancer Centre, Sydney, Australia. 7. Department of Medical Oncology, Chris O'Brien Lifehouse, Sydney, Australia. 8. Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Abstract
INTRODUCTION: Neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (MIBC) improves overall survival, but pathological response rates are low. Predictive biomarkers could select those patients most likely to benefit from NAC. Radiomics technology offers a novel, non-invasive method to identify predictive biomarkers. Our study aimed to develop a predictive radiomics signature for response to NAC in MIBC. METHODS: An institutional bladder cancer database was used to identify MIBC patients who were treated with NAC followed by radical cystectomy. Patients were classified into responders and non-responders based on pathological response. Bladder lesions on computed tomography images taken prior to NAC were contoured. Extracted radiomics features were used to train a radial basis function support vector machine classifier to learn a prediction rule to distinguish responders from non-responders. The discriminative accuracy of the classifier was then tested using a nested 10-fold cross-validation protocol. RESULTS: Nineteen patients who underwent NAC followed by radical cystectomy were found to be eligible for analysis. Of these, nine (47%) patients were classified as responders and 10 (53%) as non-responders. Nineteen bladder lesions were contoured. The sensitivity, specificity, and discriminative accuracy were 52.9±9.4%, 69.4±8.6%, and 62.1±6.1%, respectively. This corresponded to an area under the curve of 0.63±0.08 (p=0.20). CONCLUSIONS: Our developed radiomics signature demonstrated modest discriminative accuracy; however, these results may have been influenced by small sample size and heterogeneity in image acquisition. Future research using novel methods for computer-based image analysis on a larger cohort of patients is warranted.
INTRODUCTION: Neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (MIBC) improves overall survival, but pathological response rates are low. Predictive biomarkers could select those patients most likely to benefit from NAC. Radiomics technology offers a novel, non-invasive method to identify predictive biomarkers. Our study aimed to develop a predictive radiomics signature for response to NAC in MIBC. METHODS: An institutional bladder cancer database was used to identify MIBC patients who were treated with NAC followed by radical cystectomy. Patients were classified into responders and non-responders based on pathological response. Bladder lesions on computed tomography images taken prior to NAC were contoured. Extracted radiomics features were used to train a radial basis function support vector machine classifier to learn a prediction rule to distinguish responders from non-responders. The discriminative accuracy of the classifier was then tested using a nested 10-fold cross-validation protocol. RESULTS: Nineteen patients who underwent NAC followed by radical cystectomy were found to be eligible for analysis. Of these, nine (47%) patients were classified as responders and 10 (53%) as non-responders. Nineteen bladder lesions were contoured. The sensitivity, specificity, and discriminative accuracy were 52.9±9.4%, 69.4±8.6%, and 62.1±6.1%, respectively. This corresponded to an area under the curve of 0.63±0.08 (p=0.20). CONCLUSIONS: Our developed radiomics signature demonstrated modest discriminative accuracy; however, these results may have been influenced by small sample size and heterogeneity in image acquisition. Future research using novel methods for computer-based image analysis on a larger cohort of patients is warranted.
Authors: Virendra Kumar; Yuhua Gu; Satrajit Basu; Anders Berglund; Steven A Eschrich; Matthew B Schabath; Kenneth Forster; Hugo J W L Aerts; Andre Dekker; David Fenstermacher; Dmitry B Goldgof; Lawrence O Hall; Philippe Lambin; Yoganand Balagurunathan; Robert A Gatenby; Robert J Gillies Journal: Magn Reson Imaging Date: 2012-08-13 Impact factor: 2.546
Authors: Philippe Lambin; Emmanuel Rios-Velazquez; Ralph Leijenaar; Sara Carvalho; Ruud G P M van Stiphout; Patrick Granton; Catharina M L Zegers; Robert Gillies; Ronald Boellard; André Dekker; Hugo J W L Aerts Journal: Eur J Cancer Date: 2012-01-16 Impact factor: 9.162
Authors: Kenny H Cha; Lubomir Hadjiiski; Heang-Ping Chan; Alon Z Weizer; Ajjai Alva; Richard H Cohan; Elaine M Caoili; Chintana Paramagul; Ravi K Samala Journal: Sci Rep Date: 2017-08-18 Impact factor: 4.379